|会社名||Adaptimmune Therapeutics PLC （アダプティミュ―ン・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets find and genetically engineer TCR and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials which are directed to cancer testis antigens NY-ESO-1 MAGE-A4 and MAGE-A10. アダプティミュ―ン・セラピュ―ティクスは、英国のバイオ医薬品企業。独自のT細胞レセプタ―・プラットフォ―ムによる新しい癌免疫治療製品の開発に焦点を当て事業を展開。主な製品候補には、癌抗原として親和性が強化されたT細胞レセプタ―治療薬のNY-ESO-1およびNY-ESOがある。 Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.|
|本社所在地||60 Jubilee Avenue Milton Park Abingdon Oxfordshire OX14 4RY GBR|
|代表者氏名||James Julian Noble ジェームズジュリアンノーブル|
|代表者役職名||Chief Executive Officer Director 最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Adaptimmune Therapeutics PLC - ADR revenues increased from $6.4M to $17.2M. Net loss increased 54% to $64.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 41% to $47.7M (expense) Other (expense) income net decrease from $3.7M (income) to $8.3M (expense).|
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval 2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
Cowen Reaffirms “Buy” Rating for Adaptimmune Therapeutics (NASDAQ:ADAP) 2019/11/11 23:15:34 Modern Readers
Cowen reaffirmed their buy rating on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Thursday, AnalystRatings.com reports. ADAP has been the subject of several other reports. Guggenheim lowered shares of Adaptimmune Therapeutics from a buy rating to a neutral rating in a research report on Thursday, August 1st. BidaskClub lowered […]
Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds 2019/10/31 17:52:52 ACI Information Group
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry
The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug 2019/10/25 11:12:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc (NASDAQ: FREQ ) (IPOed Oct. 3) GlaxoSmithKline plc (NYSE: GSK )(FDA approved expanded use of Zejula) Novo Nordisk A/S (NYSE: NVO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 24) Acorda Therapeutics Inc NASDAQ: ACOR) (announced restructuring plan, including the elimination of 25% of its workforce) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) bluebird bio Inc (NASDAQ: BLUE ) (announced resignation of chief strategy officer) Brickell Biotech Inc (NASDAQ: BBI ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) KemPharm Inc (NASDAQ: KMPH ) MacroGenics Inc (NASDAQ: MGNX ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) OpGen Inc (NASDAQ: OPGN ) )(announcing pricing of previously-announced underwritten common stock offering) Opko Health Inc. (NASDAQ: OPK )(announced a follow-on offering) Orgenesis Inc (NASDAQ: ORGS ) Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN ) Titan Medical Inc. (NASDAQ: TMDI ) Stocks In Focus Melinta Gets FDA Nod For Baxdela Label Expansion; Launch to Be Delayed Due to Liquidity Concerns Melinta Therapeutics Inc (NASDAQ: MLNT ) announced FDA approval for Baxdela for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, caused by designated succeptible bacteria.
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug 2019/10/09 11:58:26 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 アダプティミュ―ン・セラピュ―ティクス ADAP Adaptimmune Therapeutics plc）